OncoTherapy Science
Business Services · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1-2 Higashida-cho Kawasaki-ku, Kawasaki-...Phone Number
+81 442016429Website
www.oncotherapy.co.jpRevenue
$5.7 MillionIndustry
About OncoTherapy Science
OncoTherapy Science Org Chart
Is OncoTherapy Science your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if OncoTherapy Science is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if OncoTherapy Science has recently received funding, and reach out quickly before it becomes old news!
OncoTherapy Science, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if OncoTherapy Science had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at OncoTherapy Science
Funding: Get notified immidiatlly once OncoTherapy Science has new funding data
Product Launch: Get notified when OncoTherapy Science launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on OncoTherapy Science recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
OncoTherapy Science is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OncoTherapy Science is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OncoTherapy Science.
OncoTherapy Science Tech Stack
A closer look at the technologies used by OncoTherapy Science
Top Business Services Companies
Frequently Asked Questions Regarding OncoTherapy Science
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinica... Read More